Baxter International's (BAX) BAX 111 treatment met the primary endpoint in a Phase III trial of patients with von Willebrand disease, the most common type of inherited bleeding disorder.
BAX 111 successfully treated 22 patients who experienced bleeding episodes during the trial.
Secondary endpoints included those related to additional efficacy and safety measures, pharmacokinetics and health-related quality of life.
Shares are +1.55% premarket. (PR)